series-b
Stage
2013
Founded
4
Investors
About
PDS Biotechnology is a clinical-stage biopharmaceutical company developing T-cell Stimulating Immunotherapies (TSI) for oncology and infectious disease sectors, utilizing its proprietary Versamune platform to activate T cells against cancer and infectious diseases.
Explore PDS Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.